SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is experiencing market pressure after its CagriSema obesity drug did not achieve non-inferiority against Eli Lilly's competitor in a recent trial, fueling community debate over its competitive standing. However, strong early demand for its oral Wegovy, coupled with recent regulatory actions against compounded GLP-1 alternatives and ongoing share buybacks, is leading many to see the current sell-off as an overreaction and a potential buying opportunity.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for BYSANTI, a new chemical entity with patent protection extending to 2044 for bipolar I disorder and schizophrenia. Community sentiment is largely bullish on significant upside potential and a possible short squeeze, though some express caution regarding a recent shelf offering and the drug's similarity to an existing therapy.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as community debate intensifies around recent tariff rulings and new global levies, with widespread discussion focusing on their economic impact and concerns over the company's financial stability and potential dilution ahead of upcoming disclosures.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

Enthusiasm for MoonLake Immunotherapeutics is surging following stellar Phase 2 S-OLARIS trial results for its lead drug sonelokimab in axial spondyloarthritis, with the community highlighting "best-in-class" efficacy, disease-modifying potential, strong financials, and anticipating further positive updates at its upcoming Investor Day.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following pivotal international approvals for its ANKTIVA cancer therapy in the EU and Saudi Arabia, complemented by robust revenue growth. The community is buzzing about the drug's global market expansion and potential as a chemotherapy-free cancer treatment, anticipating a substantial short squeeze.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is trending as Novo Nordisk's latest obesity drug trial underperformed Eli Lilly's, reigniting community discussion that Viking's competitive dual agonist VK2735 is now a highly attractive acquisition or partnership target for pharmaceutical giants eager to capture market share.

Arcellx, Inc is a clinical-stage biotechnology company, which provides cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. The company was founded by David M. Hilbert and Luba Zaritskaya in December 2014 and is headquartered in Redwood City MD.

Arcellx Inc

Recent positive clinical data for Arcellx's multiple myeloma CAR-T therapy, anito-cel, showcases strong efficacy and a differentiated safety profile, driving current conversation. An expanded strategic partnership and investment from Kite (Gilead), combined with the recent lifting of a partial clinical hold, reinforces market confidence and highlights the company's competitive edge in the cell therapy landscape.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is trending as its mainnet launch and institutional validation, including its Coinbase 50 index inclusion, drive bullish conviction in its utility and long-term potential, yet the community remains sharply divided amid persistent price drops leading to strong skepticism about the project's viability.

Domino's Pizza, Inc. engages in the management of a network of company-owned and franchise-owned pizza stores. It operates through the following segments: U.S. Stores, International Franchise, and Supply Chain. The U.S. Stores segment consists primarily of franchise operations. The International Franchise segment comprises a network of franchised stores. The Supply Chain segment manages regional dough manufacturing and food supply chain centers. The company was founded by James Monaghan and Thomas Stephen Monaghan in 1960 and is headquartered in Ann Arbor, MI.

Dominos Pizza Inc

Domino's Pizza is actively discussed following its recent financial results, which showed solid U.S. same-store sales growth and a 15% dividend increase, alongside reports of prominent hedge funds, including Warren Buffett's Berkshire Hathaway, increasing their positions. The community is debating if its "Hungry for MORE" strategy and market leadership can continue to drive growth amidst a mixed restaurant sector and concerns over valuation.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending amid high anticipation for its BLA resubmission to the FDA for Deramiocel, with community discussion focused on the strong HOPE-3 data and speculation regarding recent FDA policy shifts and leadership dynamics affecting the approval process.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NexGen Energy (NXE) Projected to Post Earnings on Monday

NexGen Energy (NYSE:NXE) will be releasing its Q4 2025 earnings before the market opens on Monday, March 2. (View Earnings Report at...

Big Tech Turns To Uranium As Data Center Power Demand Soars

Big Tech Turns To Uranium As Data Center Power Demand Soars Big Tech is considering supporting new uranium mining projects as companies need additional reliable power capacity for their huge data...

Beyond Tech: The Hidden Winners of the AI Energy Boom

Beyond Tech: The Hidden Winners of the AI Energy Boom Beyond Tech: The Hidden Winners of the AI Energy Boom PR Newswire VANCOUVER, BC, Feb. 17, 2026 Issued on behalf of Eagle Energy Metals...

NexGen Energy (TSE:NXE) Given New C$22.00 Price Target at Stifel Nicolaus

Stifel Nicolaus raised their target price on NexGen Energy from C$20.00 to C$22.00 and gave the stock a "buy" rating in a research report on Wednesday...

Alps Advisors Inc. Sells 1,609,680 Shares of NexGen Energy $NXE

Alps Advisors Inc. reduced its stake in NexGen Energy (NYSE:NXE - Free Report) by 9.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange...

Old West Investment Management LLC Buys 114,971 Shares of NexGen Energy $NXE

Old West Investment Management LLC increased its stake in shares of NexGen Energy (NYSE:NXE - Free Report) by 4.5% during the 3rd quarter, according to its most recent Form 13F filing with the...

NexGen Energy (NYSE:NXE) Sees Unusually-High Trading Volume - Should You Buy?

NexGen Energy (NYSE:NXE) Sees Strong Trading Volume - Here's What Happened...

NexGen Energy (TSE:NXE) Price Target Raised to C$19.00 at National Bankshares

National Bankshares upped their price objective on NexGen Energy from C$18.00 to C$19.00 and gave the stock an "outperform" rating in a report on Friday...

<ul class="summary-bullets"><li>Culper added that the company’s targeted peak annual uranium production of 29.7M lbs is “impossible to achieve.”</li><li>Culper also said that it believes NexGen's capital costs and construction timelines remain “materially understated.”</li><li>The firm estimates that company insiders and their affiliates have sold $275 million in stock in the past 3 years alone.</li></ul> Shares of NexGen Energy Ltd. (NXE) slumped as much as 10% on Friday after Culper Research announced a short position in the Canadian-based uranium exploration and development company.Culper <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://culperresearch.com/wp-content/uploads/2026/02/Culper_NXE_2-6-2026.pdf">alleged</a> that the net present value (NPV) of NexGen’s Rook I project is overstated by 43% to 62% and the company is “ultimately an insider enrichment scheme with substantial downside.”It also added that the company’s targeted peak annual uranium production of 29.7M lbs is “impossible to achieve.”<h2 class="st-heading-2">Other Allegations</h2>The Canadian company is focused on developing the Rook I Project in Saskatchewan’s Athabasca basin into the largest, low-cost producing uranium mine globally.According to Culper, Rook I’s claimed C$6.3 billion NPV is underpinned by ultra-high-grade pods discovered a decade ago, by a single contractor, analyzed at a single laboratory. There was no twin hole drilling or secondary lab analysis, it said.Despite uncovering supposedly the greatest uranium asset on the planet, NexGen’s original discovery team left the company, Culper said, while adding that this is “pretty unusual."Culper also said that it believes NexGen's capital costs and construction timelines remain “materially understated.”“The Company’s current 4-year construction timeline assumes near-flawless execution of a novel, complex underground mine plan at a remote, infrastructure-poor site in northern Saskatchewan,” it wrote.However, CEO Leigh Curyer has “serially overpromised,” Culper noted, claiming as early as 2016 that NexGen would be in production “post-2020.” The Company now promises to be producing by 2030.“We believe NexGen is, at its core, an insider enrichment vehicle masquerading as a uranium development company,” the firm said, while estimating that insiders and their affiliates have sold $275 million in stock in the past 3 years alone.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NXE">NXE stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘normal’ levels.NXE has gained over 60% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/why-did-healthcare-triangle-stock-plummet-today/cZbFkc4R4FW">Why Did Healthcare Triangle Stock Plummet 20% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Located in the uranium-rich Athabasca Basin, NexGen Energy's Rook 1 project proposes an underground mine and mill near the Arrow Deposit. | Source: Nexgen Energy

NXE Stock Tumbles After Culper Research Reveals Short Position

Culper alleged that the net present value of NexGen’s Rook I project is overstated by 43% to 62% and the company is “ultimately an insider enrichment scheme with substantial downside.”

Equity

Culper alleged that the net present value of NexGen’s Rook I project is overstated by 43% to 62% and the company is “ultimately an insider enrichment scheme with substantial downside.”


NexGen Energy (NYSE:NXE) Receives Average Rating of "Moderate Buy" from Analysts

Shares of NexGen Energy (NYSE:NXE - Get Free Report) have been given a consensus rating of "Moderate Buy" by the seven research firms that are covering the stock, Marketbeat Ratings reports. One...

NexGen Energy Ltd. engages in the acquisition, exploration and development of uranium properties. Its uranium project portfolio includes Arrow, South Arrow, Harpoon, Bow, IsoEnergy, SW1, SW2, SW3, and IsoEnergy properties. The company was founded by Leigh B. Curyer on March 8, 2011 and is headquartered in Vancouver, Canada.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.02	--	--	N/A
Q3 '25	-$0.02	-$0.16	-617.17%	MISSED
Q2 '25	-$0.03	-$0.10	-197.43%	MISSED
Q1 '25	-$0.03	-$0.06	-147.24%	MISSED
Q4 '24	-$0.03	-$0.03	-6.29%	MISSED

NXE
NexGen Energy Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest NXE News

NXENexGen Energy Ltd